Carmot Therapeutics pulls in $47m Series C

Berkeley, California-based Carmot Therapeutics, a biotechnology company focused on treating patients with metabolic diseases, has raised $47 million in Series C financing.

ByIris Dorbian

1 October 2020•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals Healthcare Briefs

Carmot Therapeutics pulls in $47m Series C

The Column Group

Related articles